ERBB2 and neoplasm: For example, Gus et al. recently showed that the newly discovered PD-L1 peptide vaccine for B cells (PDL1-Vaxx) exhibited a strong immune response and effective anti-tumour immunity in several syngeneic mouse models and worked synergistically in combination with a dual HER-2 B cell vaccine (B-Vaxx) [61,62].